Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with or without Celecoxib in dMMR/MSI-H locally advanced colorectal cancer
NCT03926338Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2019
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Started May 2019; status: recruiting.
02
Drugs
toripalimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03926338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926338.